#VisualAbstract: Adjuvant Atezolizumab Does Not Provide Benefit in Early Triple-Negative Breast Cancer
Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Tag: Breast Cancer
#VisualAbstract: Increased Survival with Trastuzumab Emtansine in Residual HER2-Positive Breast Cancer Relative to Trastuzumab Alone
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
#VisualAbstract: Camrelizumab with Chemotherapy is an Effective Neoadjuvant Therapy in Patients With Triple-Negative Breast Cancer
Click here to read this study in JAMA. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Addition of pembrolizumab to chemotherapy improves early-stage triple-negative breast cancer survival
1. In this randomized controlled trial, among patients with early-stage triple-negative breast cancer (TNBC), the addition of neoadjuvant and adjuvant ...
Inavolisib lengthens progression-free survival time in HER2-negative advanced breast cancer
1. In this randomized controlled trial, in patients with PIK3CA-mutated advanced breast cancer, the addition of inavolisib to a palbociclib-fulvestrant ...
Inavolisib-Based Therapy in PIK3CA-Mutated Advanced Breast Cancer
1. The median progression-free survival was 15.0 months in the inavolisib and 7.3 months in the placebo group, with HR ...
Statin therapy reduces radiation-induced cardiotoxicity in patients with breast cancer receiving radiotherapy
1. In a cohort of individuals with invasive ductal carcinoma (IDC) that underwent breast-conserving surgery (BCS) and adjuvant breast radiotherapy, ...
Overall Survival with Pembrolizumab in Early-Stage Triple-Negative Breast Cancer
1. The 5-year OS rate for pembrolizumab vs placebo was 86.1% vs 81.7% with HR 0.51 (significant). 2. Immune-mediated adverse ...
#VisualAbstract: Pembrolizumab Increases Survival in Early-Stage Triple-Negative Breast Cancer
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Datopotamab deruxtecan may be a novel improvement for inoperable breast cancer
1. Compared to chemotherapy, patients with inoperable hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) breast cancer receiving the antibody-drug ...